Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis

Acta Dermato-Venereologica

Volumn 88, Issue 3, 2008, Pages 279-280

  Tzung, Tien Yi ^a,b   Chen, Ching Yin ^a   Yang, Chia Yi ^c   Lo, Pei Yu ^a   Chen, Ya Hui ^a  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE DIPROPIONATE; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CALCIPOTRIOL;

ABSENCE OF SIDE EFFECTS; ADULT; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FINGER NAIL; HUMAN; LETTER; MONOTHERAPY; NAIL DISEASE; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; STATISTICAL SIGNIFICANCE; STUDENT T TEST; THERAPY EFFECT; TREATMENT OUTCOME;

BETAMETHASONE; CALCITRIOL; DERMATOLOGIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; NAIL DISEASES; PSORIASIS; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD;

EID: 44349134631     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0401     Document Type: Letter

References (14)

1. de Berker D. Management of nail psoriasis. Clin Exp Dermatol 2000; 25: 357-362.
2. Williamson L, Dalbeth N, Dockerty J, Gee BC, Weatherall R, Wordsworth BP. Nail disease in psoriatic arthritis-clinically important, potentially treatable and often overlooked. Rheumatology 2004; 43: 790-794.
3. de Jong EM, Seegers BA, Gulinck MK, Boezeman JB, van de Kerkhof PCM. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1728 patients. Dermatology 1996; 193: 300-303.
4. Sanchez Reganá M, Martin Ezquerra G, Umbert Millet P, Llambi Mateos F. Treatment of nail psoriasis with 8% clobetasol nail lacquer: positive experience in 10 patients. J Eur Acad Dermatol Venereol 2005; 19: 573-577.
5. de Jong EM, Menke HE, van Praag MC, van de Kerkhof PCM. Dystrophic psoriatic fingernails treated with 1% 5-fluorouracil in a nail penetration enhancing vehicle: a double blind study. Dermatology 1999; 199: 313-318.
6. Bianchi L, Soda R, Diluvio L, Chimenti S. Tazarotene 0.1% gel for psoriasis of the fingernails and toenails: an open, prospective study. Br J Dermatol 2003; 149: 193-227.
7. Brazzelli V, Martinoli S, Prestinari F, Borroni G. An impressive therapeutic result of nail psoriasis to acitretin. J Eur Acad Dermatol Venereol 2004; 18: 229-230.
8. Feliciani C, Zampetti A, Forleo P, Cerritelli L, Amerio P, Proietto G, et al. Nail psoriasis: combined therapy with systemic cyclosporine and topical calcipotriol. J Cutan Med Surg 2004; 8: 122-125.
9. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-1374.
10. Rigopoulos D, Ioannides D, Prasitis N, Katsambas A. Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream. Acta Derm Venereol 2002; 82: 140.
11. Guenther L, Cambazard F, van de Kerkhof PCM, Snellman E, Kragballe K, Chu AC, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002; 147: 316-323.
12. Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003; 49: 206-212.
13. van de Kerkhof PCM, de Hoop D, de Korte J, Cobelens SA, Kuipers MV. Patient compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology 2000; 200: 292-298.
14. Rragballe K, Austad J, Barnes L, Bibby A, de la Brassinne M, Cambazard F, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet®/Daivobe®/Taclonex®) in the treatment of psoriasis vulgaris. Br J Dermatol 2006; 154: 1155-1160.